Uni Biosciences

Executive Summary

Uni Biosciences is a Beijing-based biotechnology company dedicated to discovering and developing novel therapeutic antibodies for oncology and immunology. Founded in 2017, the company leverages advanced antibody engineering platforms to create biologic drug candidates with improved efficacy and safety profiles. Operating at the preclinical stage, Uni Biosciences focuses on addressing unmet medical needs through targeted therapies. The company's pipeline, though undisclosed, is likely centered on immune-oncology targets such as PD-1/PD-L1, CTLA-4, or novel checkpoints, given the competitive landscape in China. With a team of 50-200 employees, Uni Biosciences aims to advance its lead candidates into clinical trials within the next 12-18 months, positioning itself for potential partnerships or licensing deals with larger pharmaceutical companies. However, as a preclinical company with no disclosed funding rounds, the path to commercialization remains uncertain, and significant capital will be required to fund IND-enabling studies and early-phase clinical trials.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Candidate60% success
• Q4 2027First-in-Human Phase 1 Trial Initiation50% success
• TBDStrategic Licensing or Collaboration Agreement40% success